Stifel Nicolaus Lowers 10x Genomics (NASDAQ:TXG) Price Target to $18.00

10x Genomics (NASDAQ:TXG) had its price target cut by equities research analysts at Stifel Nicolaus from $21.00 to $18.00 in a report released on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 53.57% from the company’s current price.

A number of other analysts also recently issued reports on TXG. Weiss Ratings restated a “sell (e+)” rating on shares of 10x Genomics in a report on Saturday, February 1st. UBS Group decreased their price target on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a research note on Thursday. Morgan Stanley dropped their price objective on 10x Genomics from $30.00 to $28.00 and set an “overweight” rating on the stock in a research note on Monday, January 13th. Leerink Partners downgraded 10x Genomics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $25.00 to $12.00 in a research report on Thursday. Finally, Barclays dropped their price target on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Monday. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $21.21.

10x Genomics Trading Down 2.3 %

Shares of TXG stock traded down $0.28 during trading on Thursday, hitting $11.72. The company’s stock had a trading volume of 1,314,605 shares, compared to its average volume of 2,286,820. The company has a market cap of $1.42 billion, a PE ratio of -7.68 and a beta of 1.85. The business has a fifty day moving average of $14.82 and a 200-day moving average of $17.47. 10x Genomics has a 52 week low of $10.80 and a 52 week high of $51.22.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. As a group, research analysts predict that 10x Genomics will post -1.43 EPS for the current year.

Hedge Funds Weigh In On 10x Genomics

Large investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its holdings in 10x Genomics by 451.8% in the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock valued at $35,000 after purchasing an additional 1,265 shares during the period. Capital Performance Advisors LLP purchased a new stake in shares of 10x Genomics in the third quarter worth $35,000. Blue Trust Inc. boosted its stake in 10x Genomics by 136.5% during the third quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock valued at $40,000 after buying an additional 1,025 shares during the period. Signaturefd LLC grew its position in 10x Genomics by 424.6% during the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock worth $26,000 after buying an additional 1,452 shares in the last quarter. Finally, Venturi Wealth Management LLC grew its position in 10x Genomics by 1,108.9% during the third quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company’s stock worth $55,000 after buying an additional 2,240 shares in the last quarter. 84.68% of the stock is currently owned by institutional investors.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.